Furthermore, studies from both in vivo and in vitro of PCa have shown that the loss of AR or treatment with AR antagonist Enzalutamide leads to enhanced AKT signaling [78,118,121], supporting an activation of PI3K-AKT-mTOR signal to resist AR targeted therapy. This evidence concerns the gene AKT1 and posterior cortical atrophy.